All genetic analyses were performed in GLP-environment at the Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, located at the Montreal Heart Institute (Montreal, Canada). Details regarding sample management, DNA isolation and genotyping are provided in the supplementary materials . The genotyping strategy for the HFN was to use a variety of genotyping platforms including commercial and custom assays which were performed on all participants across all clinical trials.10 (link)-12 (link) Genotyping included broad-based genotyping approaches (Illumina HumanOmni2.5-8 BeadChip, Illumina HumanExome v1.0 Beadchip, Sequenom iPLEX® ADME PGx Panel) and complementary custom Sequenom candidate gene panels. For the current substudy, to maximize statistical power, we limited our investigations to common and rare genetic variants from these platforms in 19 candidate genes that were selected based on their potential role to modulate the pharmacodynamics and pharmacokinetics of furosemide or renal function (Table 1 ).1 (link),13 (link) Following the quality checks and genetic data cleanup process (supplementary materials ), 2040 SNPs from these genes were included in the analyses.
Humanexome v1.0 beadchip
Manufactured by Labcorp
The HumanExome v1.0 Beadchip is a microarray-based genomic technology designed for high-throughput genotyping of known genetic variants. It provides comprehensive coverage of coding regions across the human genome, enabling researchers to interrogate genetic variations associated with a wide range of diseases and traits.
Automatically generated - may contain errors
Lab products found in correlation
2 protocols using humanexome v1.0 beadchip
1
Pharmacogenomic Analysis of Furosemide Response
2
Pharmacogenomic Analysis of Furosemide Response
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
All genetic analyses were performed in GLP-environment at the Université de Montréal Beaulieu-Saucier Pharmacogenomics Centre, located at the Montreal Heart Institute (Montreal, Canada). Details regarding sample management, DNA isolation and genotyping are provided in the supplementary materials . The genotyping strategy for the HFN was to use a variety of genotyping platforms including commercial and custom assays which were performed on all participants across all clinical trials.10 (link)-12 (link) Genotyping included broad-based genotyping approaches (Illumina HumanOmni2.5-8 BeadChip, Illumina HumanExome v1.0 Beadchip, Sequenom iPLEX® ADME PGx Panel) and complementary custom Sequenom candidate gene panels. For the current substudy, to maximize statistical power, we limited our investigations to common and rare genetic variants from these platforms in 19 candidate genes that were selected based on their potential role to modulate the pharmacodynamics and pharmacokinetics of furosemide or renal function (Table 1 ).1 (link),13 (link) Following the quality checks and genetic data cleanup process (supplementary materials ), 2040 SNPs from these genes were included in the analyses.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!